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OBJECTIVES: Hypertension, the leading risk factor for global disease burden, 
affects 20% of Canadians. Approximately 10-15% of hypertensive patients are 
treatment resistant. Controlled clinical trial data demonstrate that catheter-
based renal denervation (RDN) leads to clinically significant blood pressure 
reductions of 32/12 mmHg in treatment resistant patients. The goal of this study 
was to predict the long-term risk reduction and the lifetime cost-effectiveness of 
RDN in a Canadian setting. METHODS: A Markov model with monthly cycles was 
used to estimate: a) ten-year relative risks for clinical endpoints and lifetime 
costs; b) unadjusted and quality-adjusted life expectancy (LYs and QALYs); and c) 
the incremental cost-effectiveness ratio (ICER) of RDN compared to optimal 
pharmacotherapy (OPT) from a Canadian provincial health care system 
perspective. Transition probabilities were based on multivariable risk equations 
(including Framingham) and clinical inputs were based on the Symplicity HTN-2 
trial cohort characteristics. Cost data and utility scores were derived from 
published literature and provincial public databases. The clinical endpoints 
modeled were stroke, myocardial infarction (MI), all coronary artery disease 
(CHD), heart failure (HF), and end-stage renal disease (ESRD). Costs, life 
expectancy, and ICERs were discounted at 3%, and sensitivity and threshold 
analyses were conducted. RESULTS: The 10-year relative risks for RDN versus 
OPT were: stroke 0.70, MI 0.68, all-CHD and HF 0.78, respectively, and ESRD 0.72. 
The lifetime costs of OPT and RDN were $62,076 and $65,471, respectively. RDN 
increased QALYs by 0.60 and LYs by 0.65 compared to OPT. ICERs for RDN were 
$5,648 /QALY and $5,171/LY. Considering willingness-to-pay thresholds of 
$25,000 and $50,000/QALY, RDN was cost-effective down to effect sizes of 18.2 
and 12.2 mmHg systolic blood pressure reductions, respectively. CONCLUSIONS: 
Catheter-based renal denervation, across a wide spectrum of assumptions, is a 
cost-effective option for the treatment of resistant hypertension patients in 
Canada.  
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OBJECTIVES: Ticagrelor showed a significant reduction in major cardiac events 
in patients with acute coronary syndrome (ACS) compared with clopidogrel in 
the Platelet Inhibition and Patient Outcomes (PLATO) trial. Our aim was to assess 
the cost-effectiveness of ticagrelor compared to brand and generic clopidogrel in 
ACS patients from the perspective of the publically funded Canadian health care 
system. METHODS: A two-part model was developed consisting of a one-year 
decision tree and a lifetime Markov model. Within the decision tree, patients 
remained event-free, experienced a non-fatal myocardial infarction (MI), a non-
fatal stroke, or death due to vascular or non-vascular related causes based on 
data from the PLATO trial. The lifetime Markov model followed these patients 
and allowed subsequent MI, stroke and death. Patient level EQ5D (utility) and 
resource use were derived from PLATO. Transition probabilities and Canadian 
unit costs specific were derived from published sources. Univariate and 
probabilistic sensitivity analyses were conducted. RESULTS: In the base case 
analysis, one-year of treatment with ticagrelor post-ACS resulted in a lifetime 
incremental cost-effectiveness ratio (ICER) of $9,745 per quality adjusted life year 
(QALY) gained, assuming the generic cost for clopidogrel. Compared to brand 
clopidogrel, the ICER was $1,523 per QALY gained. A probabilistic sensitivity 
analysis demonstrated a 93% probability of being below $20,000 per QALY gained 
and a 99% probability of being below $30,000 per QALY gained. CONCLUSIONS: 
Ticagrelor is a clinically superior and cost-effective option compared to brand 
and generic clopidogrel for the prevention of major cardiovascular events among 
ACS patients in Canada. These results strongly support the reimbursement of 
ticagrelor for this indication.  
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OBJECTIVES: Severe Aortic stenosis (AS) refers to pathological, clinical and 
pathophysiological changes associated with decreased aortic valve area, as a 
consequence of calcification. Transcatheter Aortic Valve Implantation (TAVI) –is 
targeted at individuals deemed unsuitable candidates for Surgical Aortic Valve 
Replacement (SAVR) as an alternative to Medical Management (MM). Recently 
published studies have demonstrated TAVI to be a good use of health care 
resources in other countries. Our primary objective was to estimate the cost-
effectiveness of TAVI for AS compared with MM in Colombia. METHODS: We 
used an Excel-based probabilistic decision analytic model to evaluate the cost-
effectiveness of TAVI for AS compared to MM. A 3 year update of the landmark 
PARTNER B randomized study was used to inform treatment specific mortality. 
Rates for adverse events and pacemaker use were taken from a large 
multinational registry. Model inputs included costs and resource use for 
inpatient and outpatient treatment in Colombia, and were taken from the 
published literature and local sources. Utilities and quality of life were estimated 
from the PARTNER B study. Additional parameters on local epidemiology were 
obtained from international peer-reviewed literature and private and public 
official databases. Cost-effectiveness was assessed from a third-payer 
perspective and over a 20-year time horizon. RESULTS: Our discounted results 
show that over a patients lifetime, individuals on TAVI obtained 2.55 QALYs and 
those on MM, 0.83 QALYs. The associated lifetime costs for both interventions 
were COP$92 million and COP$8 million for TAVI and MM respectively. The 
incremental cost-effectiveness ratio was therefore $49 million per QALY gained. 
Although TAVI costs were much higher than MM, TAVI improved the probability 
of survival by 12%, resulting in an expected survival gain of 1.25 years. 
CONCLUSIONS: This analysis suggests that TAVI is a cost-effective alternative 
for the treatment of AS in patients unsuitable for SAVR in Colombia.  
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban relative to 
warfarin, for the prevention of stroke in patients with AF. METHODS: A Markov 
model demonstrating the progression of AF patients from healthy state towards 
embolic and bleeding events and to death was adapted to the Turkish setting. 
The cycle length was set as three-months. The analysis was undertaken from a 
payer perspective. Event rates and treatment effects were derived from the 
ROCKET AF clinical trial. Utility values for events were based on international 
literature. Costs of each health state included year 2012 local costs of 
medications, monitoring and events (Mid-2012 USD currency rate was used). 
Incremental cost effectiveness ratios (ICER) per life year (LY) and quality-
adjusted LY (QALY) gained were calculated. One-way sensitivity analyses were 
conducted to test the robustness of the model. The time horizon was life time 
period. Discount rate was set at 3.5% for economic and clinical inputs. 
Willingness-to-pay (WTP) threshold was set as twice the local gross domestic 
product per capita (US$20,888). RESULTS: The total cost of rivaroxaban-treated 
patients was US$1,065 higher compared to warfarin. Additional drug acquisition 
costs (US$3,083) caused by rivaroxaban were mainly offset by reduced 
monitoring (US$1,902) and event costs (US$116). Moreover, rivaroxaban was 
associated with increments of 0.065LYs and 0.055QALY leading to an ICER of 
US$16,362/LY gained and US$19,500/QALY gained. Sensitivity analyses showed 
that the cost-effectiveness results are fairly insensitive to most inputs. The 
changes in the cost of embolic and hemorrhagic events had almost no effect on 
ICER values. The ICER value was sensitive to the cost and frequency of 
monitoring in warfarin patients. CONCLUSIONS: Rivaroxaban, with its cost-
saving effect on monitoring, reducing the frequencies of clinical events, 
improvement in LYs and QALYs, and ICER values below WTP threshold, is 
suggested to be a cost-effective alternative for the prevention of stroke in AF.  
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OBJECTIVES: Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor, represents 
a new OAC option for stroke prevention in patients with non-valvular atrial 
fibrillation (AF). The objective of this study was to assess the cost effectiveness of 
rivaroxaban in three European countries. METHODS: Markov models for Greece, 
Spain and Slovakia were developed to estimate the cost-effectiveness of 
rivaroxaban and vitamin K antagonist (VKA) treatment from the payer 
perspective of each country. In all three models, baseline event rates (adjusted to 
three month cycles) and relative treatment effects (HRs) were derived from the 
safety on treatment analysis of the ROCKET AF study and available literature. 
Utility values for events used to estimate the quality adjusted life years (QALY) 
were based on literature. Each model used costs and other economic inputs 
specific for that country. One-way and probabilistic sensitivity analyses (PSA) 
were performed. A subpopulation analysis was also conducted for Greece and 
Spain comparing rivaroxaban with VKA in patients with poor INR control 
(patients who spend less than 65% of time in therapeutic range). PSA were also 
performed to assess the robustness of the findings. RESULTS: Base-case analyses 
indicated that rivaroxaban was cost-effective with ICERs of €4,517, €17,432 and 
€11,274 per QALY compared with adjusted-dose warfarin for Greece, Slovakia 
and Spain, respectively. Rivaroxaban was found to be cost-effective in at 
willingness-to-pay thresholds for each country. The analyses conducted for 
patients with poor INR control found that rivaroxaban dominated VKA in this 
patient population in Greece, whereas an ICER of €2144 per QALY compared with 
VKAs were seen in Spain. PSA confirmed the robustness of the results. 
CONCLUSIONS: Rivaroxaban is a cost-effective alternative to VKAs for the 
prevention of stroke in patients with AF, particularly for those patients with poor 
INR control.  
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